2. Search Result
Search Result
Results for "

PhD 2

" in MedChemExpress (MCE) Product Catalog:

34

Inhibitors & Agonists

1

Peptides

2

Natural
Products

1

Recombinant Proteins

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N1477
    Dencichine

    Dencichin; ODAP

    		 HIF/HIF Prolyl-Hydroxylase Neurological Disease
    Dencichin is a non-protein amino acid originally extracted from Panax notoginseng, and can inhibit HIF-prolyl hydroxylase-2 (PHD-2) activity.
    Dencichine
  • HY-P5648
    PhD2

    		Bacterial Infection
    PhD2 is an antimicrobial peptide derived from monkey white blood cells. PhD2 has activity against bacteria and fungus Candida albicans .
    PhD2
  • HY-170917
    PHD2-IN-4

    		HIF/HIF Prolyl-Hydroxylase
    PHD2-IN-4 (compound 1) is a PHD2 inhibitor. PHD2-IN-4 inhibits PHD2 with an IC50 of 4 nM. PHD2-IN-4 is potential for chronic kidney disease research .
    PHD2-IN-4
  • HY-15692
    PHD2-IN-3

    		HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease
    PHD2-IN-3 (compound 2) is a PHD2 inhibitor. PHD2-IN-3 can be used for study of anemia .
    PHD2-IN-3
  • HY-162438
    PHD2-IN-2

    		HIF/HIF Prolyl-Hydroxylase Metabolic Disease
    PHD2-IN-2 (Compound 12) is a PHD2 inhibitor, with an IC50 of 34.3 nM. PHD2-IN-2 has high erythropoietin (EPO) inducing activity, with an EC50 of 6.79 μM. PHD2-IN-2 can be used for the research of anemia, ischemia, and hypoxia .
    PHD2-IN-2
  • HY-176408
    PHD2-IN-5

    		HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease
    PHD2-IN-5 (compound 22) is a potent PHD2 inhibitor with an IC50 of 0.82 μM. PHD2-IN-5 can be used in the study of renal anemia .
    PHD2-IN-5
  • HY-155009
    PHD2-IN-1

    		HIF/HIF Prolyl-Hydroxylase Others
    PHD2-IN-1 is a potent and orally active inhibitor of HIF prolyl hydroxylase 2 (PHD2) with an IC50 of 22.53 nM. PHD2-IN-1 can be used for anemia research .
    PHD2-IN-1
  • HY-177271
    PHD2-IN-6

    		HIF/HIF Prolyl-Hydroxylase Inflammation/Immunology
    PHD2-IN-6 (Example 89) is a HIF prolyl hydroxylase 2 (PHD2) inhibitor with an IC50 of 31.6  nM. PHD2-IN-6 stimulates encoding erythropoietin (EPO) production. PHD2-IN-6 can be used for inflammatory diseases like inflammatory bowel disease (IBD) and rheumatoid arthritis research .
    PHD2-IN-6
  • HY-144332
    PHD2/HDACs-IN-1

    		HDAC HIF/HIF Prolyl-Hydroxylase Cancer
    PHD2/HDACs-IN-1 is a potent PHD2/HDACs hybrid inhibitor (IC50s of 1.15 μM, 19.75 μM, 26.60 μM and 15.98 μM for PHD2, HDAC1, HDAC2 and HDAC6, respectively). PHD2/HDACs-IN-1 is a low-toxicity renoprotective agent for research of cisplatin-induced acute kidney injury (AKI) .
    PHD2/HDACs-IN-1
  • HY-139993
    HIF-PHD-IN-2

    		HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease
    HIF-PHD-IN-2 (compound 25) is a potent PHD inhibitor with IC50s of <100 nM for PHD1, PHD2 and PHD3, respectively .
    HIF-PHD-IN-2
  • HY-N6030
    (Rac)-Dencichine

    (Rac)-Dencichin; (Rac)-ODAP

    		 HIF/HIF Prolyl-Hydroxylase Others
    (Rac)-Dencichine ((Rac)-Dencichin) is the racemate of Dencichin. Dencichin is a non-protein amino acid originally extracted from Panax notoginseng, and can inhibit HIF-prolyl hydroxylase-2 (PHD-2) activity .
    (Rac)-Dencichine
  • HY-119351
    BNS

    		HIF/HIF Prolyl-Hydroxylase Others
    BNS is a cell penetrant, potent and selective PHD2 (prolyl-hydroxylase 2) inhibitor .
    BNS
  • HY-120110
    IOX4
    5+ Cited Publications

    		 HIF/HIF Prolyl-Hydroxylase Neurological Disease Inflammation/Immunology
    IOX4 is a selective HIF prolyl-hydroxylase 2 (PHD2) inhibitor with an IC50 value of 1.6 nM, induces HIFα in cells and in wildtype mice with marked induction in the brain tissue. IOX4 competes with and displaces 2-oxoglutarate (2OG) at the active site of PHD2 .
    IOX4
  • HY-101023
    MK-8617
    3 Publications Verification

    		 HIF/HIF Prolyl-Hydroxylase Inflammation/Immunology
    MK-8617 is an orally active pan-inhibitor of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) with an IC50 of 1 nM for PHD2.
    MK-8617
  • HY-156526
    PHD-IN-1

    		HIF/HIF Prolyl-Hydroxylase Others
    PHD-IN-1 (compound 80) is a potent inhibitor of PHD2，with an IC50 value of ≤5 nM. PHD-IN-1 shows EC50s of 2.5 μM in EPO Elisa assay both in Caco2-HIFla-HiBiT-clone-1 cells and Hep3B cells，respectively .
    PHD-IN-1
  • HY-12832
    JNJ-42041935

    		HIF/HIF Prolyl-Hydroxylase Inflammation/Immunology
    JNJ-42041935 is a potent, competitive and selective inhibitor of prolyl hydroxylase PHD; inhibits PHD1, PHD2, and PHD3 with pKi values of 7.91±0.04, 7.29 ±0.05, and 7.65±0.09, respectively.
    JNJ-42041935
  • HY-131346
    HIF-PHD-IN-1

    		HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease
    HIF-PHD-IN-1 is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase domain (HIF-PHD), with an IC50 of 54 nM for hHIF-PHD2. HIF-PHD-IN-1 is promising therapeutic agents for renal anemia .
    HIF-PHD-IN-1
  • HY-170915
    DDO-3055

    		HIF/HIF Prolyl-Hydroxylase Others
    DDO-3055 is an orally active PHD2 inhibitor that can be used in the research of anemia associated with chronic kidney disease .
    DDO-3055
  • HY-12315
    N-Oxalylglycine

    N-Oxaloglycine

    		 Histone Demethylase HIF/HIF Prolyl-Hydroxylase Cancer
    N-Oxalylglycine (N-Oxaloglycine) is a Jumonji C-domain-containing histone lysine demethylase inhibitor. N-Oxalylglycine inhibits JMJD2A, JMJD2C and JMJD2D. N-Oxalylglycine also inhibits HIF prolylhydroxylase domain-1 (PHD-1) and PHD-2, with an IC50 of 2.1 μM and 5.6 μM, respectively .
    N-Oxalylglycine
  • HY-112144
    TP0463518
    1 Publications Verification

    		 HIF/HIF Prolyl-Hydroxylase Metabolic Disease Inflammation/Immunology
    TP0463518 is an orally active, competitive pan-inhibitor of hypoxia-inducible factor prolyl hydroxylases PHD1/2/3. TP0463518 competitively inhibits human PHD1 (IC50=18 nM), PHD2 (Ki=5.3 nM), and PHD3 (IC50=63 nM), and targets monkey PHD2 with an IC50 of 22 nM. TP0463518 inhibits PHD-catalyzed hydroxylation to stabilize HIFα, thereby upregulating erythropoietin (EPO) expression and enhancing intestinal iron absorption (such as increased DMT-1 and dCYTb expression), improving anemia. TP0463518 is mainly used for the research of renal anemia and inflammatory anemia .
    TP0463518
  • HY-123422
    GSK360A

    		HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease
    GSK360A is a potent and orally active HIF-PHD inhibitor with IC50 values of 10, 100, and 126 nM for PHD1, PHD2, and PHD3, respectively. GSK360A activates the HIF-1 alpha pathway and protect the failing heart after myocardial infarction (MI) .
    GSK360A
  • HY-172257
    HIF-PHD-IN-4

    		HIF/HIF Prolyl-Hydroxylase Cancer
    HIF-PHD-IN-4 (Compound 13) is an orally active PHD2 inhibitor with an IC50 of 100 nM. HIF-PHD-IN-4 can effectively enhance the mobilization of hematopoietic stem cells induced by G-CSF in mice at a dose of 2 mg/kg. HIF-PHD-IN-4 is suitable for research in the field of tumor therapy .
    HIF-PHD-IN-4
  • HY-12315R
    N-Oxalylglycine (Standard)

    		Histone Demethylase HIF/HIF Prolyl-Hydroxylase Cancer
    N-Oxalylglycine (Standard) is the analytical standard of N-Oxalylglycine. This product is intended for research and analytical applications. N-Oxalylglycine (N-Oxaloglycine) is a Jumonji C-domain-containing histone lysine demethylase inhibitor. N-Oxalylglycine inhibits JMJD2A, JMJD2C and JMJD2D. N-Oxalylglycine also inhibits HIF prolylhydroxylase domain-1 (PHD-1) and PHD-2, with an IC50 of 2.1 μM and 5.6 μM, respectively .
    N-Oxalylglycine (Standard)
  • HY-170914
    JPHM-2-167

    		HIF/HIF Prolyl-Hydroxylase Metabolic Disease
    JPHM-2-167 (Compound 11) is a selective PHD (prolyl hydroxylase domain enzyme) inhibitor. JPHM-2-167 inhibits PHD2, PHD3 with IC50s of 0.253 μM and 3.95 μM, respectively. JPHM-2-167 can be used for chronic kidney disease .
    JPHM-2-167
  • HY-W747868
    Molidustat sodium

    		HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease
    Molidustat sodium is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC50 values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat sodium can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat sodium can be utilized in the research of renal anemia .
    Molidustat sodium
  • HY-12654
    Molidustat
    5+ Cited Publications

    BAY 85-3934

    		 HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease
    Molidustat (BAY 85-3934) is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC50 values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat can be utilized in the research of renal anemia .
    Molidustat
  • HY-158341
    IOX5

    		HIF/HIF Prolyl-Hydroxylase Apoptosis Cancer
    IOX5 is a selective prolyl hydroxylase (PHD) inhibitor with an IC50 of 0.19 μM for PHD2. IOX5 stabilizes HIF-1α in acute myeloid leukemia (AML) cells, inhibits cell proliferation and induces apoptosis. IOX5 has anti-leukemia activity .
    IOX5
  • HY-15641
    FG-2216
    5+ Cited Publications

    IOX3; YM311

    		 HIF/HIF Prolyl-Hydroxylase Metabolic Disease
    FG-2216 (IOX3) is a potent and orally active inhibitor of HIF prolyl hydroxylase-2 (PHD2), with an IC50 of 3.9 μM. FG-2216 induces robust erythropoietin and modest fetal hemoglobin in vivo .
    FG-2216
  • HY-12654R
    Molidustat (Standard)

    		HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease
    Molidustat (Standard) is the analytical standard of Molidustat. This product is intended for research and analytical applications. Molidustat (BAY 85-3934) is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC50 values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat can be utilized in the research of renal anemia .
    Molidustat (Standard)
  • HY-15468A
    IOX2 sodium

    		HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease Cancer
    IOX2 sodium is a specific prolyl hydroxylase-2 (PHD2) inhibitor with IC50 of 22 nM. IOX2 sodium regulates platelet function and arterial thrombosis by upregulating HIF-1α expression and inhibiting ROS production. IOX2 sodium can be used in the study of thrombotic diseases .
    IOX2 sodium
  • HY-15468
    IOX2
    Maximum Cited Publications
    17 Publications Verification

    		 HIF/HIF Prolyl-Hydroxylase Cancer
    IOX2, a chemical probe, is a specific prolyl hydroxylase-2 (PHD2) inhibitor with IC50 of 22 nM. IOX2 regulates platelet function and arterial thrombosis by upregulating HIF-1α expression and inhibiting ROS production. IOX2 can be used in the study of thrombotic diseases .
    IOX2
  • HY-15641R
    FG-2216 (Standard)

    		HIF/HIF Prolyl-Hydroxylase Metabolic Disease
    FG-2216 (Standard) is the analytical standard of FG-2216. This product is intended for research and analytical applications. FG-2216 (IOX3) is a potent and orally active inhibitor of HIF prolyl hydroxylase-2 (PHD2), with an IC50 of 3.9 μM. FG-2216 induces robust erythropoietin and modest fetal hemoglobin in vivo .
    FG-2216 (Standard)
  • HY-168533
    ZG-2305

    		HIF/HIF Prolyl-Hydroxylase Metabolic Disease
    ZG-2305 is a potent, orally active and selective factor inhibiting hypoxia-inducible factor (FIH) inhibitor with Ki values of 79.6, 2786 nM for FIH, PHD2, respectively. ZG-2305 increases the expression of EGLN3 gene. ZG-2305 decreases the cellular triglycerides levels and reduces lipid accumulation. ZG-2305 has the potential for the research of obesity and fatty liver disease .
    ZG-2305
  • HY-170522
    ISM012-042

    		HIF/HIF Prolyl-Hydroxylase Inflammation/Immunology
    ISM012-042 is an orally active PHD1 and PHD2 inhibitor with IC50 values of 1.9 and 2.5 nM, respectively. ISM012-042 (2.5 μM) can protect Caco-2 cells from DSS-induced barrier disruption. In lipopolysaccharide (LPS)-induced mouse bone marrow-derived dendritic cells (BMDC), ISM012-042 has anti-inflammatory effects and can dose-dependently reduce the expression of IL-12 subunit IL-12p35 and TNF. ISM012-042 restores intestinal barrier function and alleviates intestinal inflammation in various experimental colitis models. ISM012-042 can be used for intestinal mucosal repair and research into immune diseases .
    ISM012-042

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: